Recruiting

Testing a new medication for advanced salivary gland cancer

Plain-English translation of NCT06805617 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a medication that works by blocking cancer cell growth, in people with advanced salivary gland cancer that has spread to other parts of the body or cannot be surgically removed. The medication has been used to treat lung cancer but is not yet approved by the FDA for salivary gland cancer. This study will help doctors understand if the treatment works and is safe for this type of cancer.

Advanced salivary gland cancers are difficult to treat and have limited treatment options. This medication may offer a new way to slow or stop cancer growth by working differently than standard chemotherapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with salivary gland cancer that is advanced, has spread to other parts of your body, or cannot be surgically removed
you are 18 years or older (there is no upper age limit)
you are in generally good health with an ability to care for yourself (Eastern Cooperative Oncology Group performance status 0–1)
your blood counts, liver function, and kidney function are adequate (tested by recent blood work)
you have evidence that your cancer is growing or worsening within the past 12 months
you have at least one tumor that can be measured by imaging scans and is at least 1 centimeter in size

You likely don't qualify if…

you have received certain anti-cancer monoclonal antibody treatments within the past 3 weeks without adequate recovery
your blood cell counts, liver function, or kidney function are severely abnormal
you have excessive protein in your urine or abnormal blood clotting tests
you have cancer that has spread to the brain or central nervous system
you cannot provide a tumor tissue sample or have not recovered adequately from prior cancer treatments

What participation looks like

You will visit the clinic regularly over approximately 3 years to receive the medication, typically given once daily in 21-day cycles. You will have imaging tests (CT, MRI, or PET scans) every 9 weeks to see if the cancer is responding, blood tests, urine tests, and possibly a tumor biopsy. After you finish taking the medication, you will continue follow-up visits every 12 weeks to monitor your health.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts